Cargando…

Estimation of Health and Economic Benefits of a Small Automatic External Defibrillator for Rapid Treatment of Sudden Cardiac Arrest (SMART): A Cost-Effectiveness Analysis

BACKGROUND: Sudden cardiac arrest (SCA) occurs in 0.4% of the general population and up to 6% or more of at-risk groups each year. Early CPR and defibrillation improves SCA outcomes but access to automatic external defibrillators (AEDs) remains limited. METHODS: Markov models were used to evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaker, Marcus S., Abrams, Elissa M., Oppenheimer, John, Singer, Alexander G., Shaker, Matthew, Fleck, Daniel, Greenhawt, Matthew, Grove, Evan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907482/
https://www.ncbi.nlm.nih.gov/pubmed/35282380
http://dx.doi.org/10.3389/fcvm.2022.771679
_version_ 1784665654316498944
author Shaker, Marcus S.
Abrams, Elissa M.
Oppenheimer, John
Singer, Alexander G.
Shaker, Matthew
Fleck, Daniel
Greenhawt, Matthew
Grove, Evan
author_facet Shaker, Marcus S.
Abrams, Elissa M.
Oppenheimer, John
Singer, Alexander G.
Shaker, Matthew
Fleck, Daniel
Greenhawt, Matthew
Grove, Evan
author_sort Shaker, Marcus S.
collection PubMed
description BACKGROUND: Sudden cardiac arrest (SCA) occurs in 0.4% of the general population and up to 6% or more of at-risk groups each year. Early CPR and defibrillation improves SCA outcomes but access to automatic external defibrillators (AEDs) remains limited. METHODS: Markov models were used to evaluate the cost-effectiveness of a portable SMART (SMall AED for Rapid Treatment of SCA) approach to early SCA management over a life-time horizon in at-risk and not at-risk populations. Simulated patients (n = 600,000) who had not received an implantable cardioverter defibrillator (ICD) were randomized to a SMART device with CPR prompts or non-SMART approaches. Annual SCA risk was varied from 0.2 to 3.5%. Analysis was performed in a US economy from both societal (SP) and healthcare (HP) perspectives to evaluate the number of SCA fatalities prevented by SMART, and SMART cost-effectiveness at a threshold of $100,000/Quality Adjusted Life Year (QALY). RESULTS: A SMART approach was cost-effective when annual SCA risk exceeded 1.51% (SP) and 1.62% (HP). The incremental cost-effectiveness ratios (ICER) were $95,251/QALY (SP) and $100,797/QALY (HP) at a 1.60% SCA annual risk. At a 3.5% annual SCA risk, SMART was highly cost-effective from both SP and HP [ICER: $53,925/QALY (SP), $59,672/QALY (HP)]. In microsimulation, SMART prevented 1,762 fatalities across risk strata (1.59% fatality relative risk reduction across groups). From a population perspective, SMART could prevent at least 109,839 SCA deaths in persons 45 years and older in the United States. CONCLUSIONS AND RELEVANCE: A SMART approach to SCA prophylaxis prevents fatalities and is cost-effective in patients at elevated SCA risk. The availability of a smart-phone enabled pocket-sized AED with CPR prompts has the potential to greatly improve population health and economic outcomes.
format Online
Article
Text
id pubmed-8907482
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89074822022-03-11 Estimation of Health and Economic Benefits of a Small Automatic External Defibrillator for Rapid Treatment of Sudden Cardiac Arrest (SMART): A Cost-Effectiveness Analysis Shaker, Marcus S. Abrams, Elissa M. Oppenheimer, John Singer, Alexander G. Shaker, Matthew Fleck, Daniel Greenhawt, Matthew Grove, Evan Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Sudden cardiac arrest (SCA) occurs in 0.4% of the general population and up to 6% or more of at-risk groups each year. Early CPR and defibrillation improves SCA outcomes but access to automatic external defibrillators (AEDs) remains limited. METHODS: Markov models were used to evaluate the cost-effectiveness of a portable SMART (SMall AED for Rapid Treatment of SCA) approach to early SCA management over a life-time horizon in at-risk and not at-risk populations. Simulated patients (n = 600,000) who had not received an implantable cardioverter defibrillator (ICD) were randomized to a SMART device with CPR prompts or non-SMART approaches. Annual SCA risk was varied from 0.2 to 3.5%. Analysis was performed in a US economy from both societal (SP) and healthcare (HP) perspectives to evaluate the number of SCA fatalities prevented by SMART, and SMART cost-effectiveness at a threshold of $100,000/Quality Adjusted Life Year (QALY). RESULTS: A SMART approach was cost-effective when annual SCA risk exceeded 1.51% (SP) and 1.62% (HP). The incremental cost-effectiveness ratios (ICER) were $95,251/QALY (SP) and $100,797/QALY (HP) at a 1.60% SCA annual risk. At a 3.5% annual SCA risk, SMART was highly cost-effective from both SP and HP [ICER: $53,925/QALY (SP), $59,672/QALY (HP)]. In microsimulation, SMART prevented 1,762 fatalities across risk strata (1.59% fatality relative risk reduction across groups). From a population perspective, SMART could prevent at least 109,839 SCA deaths in persons 45 years and older in the United States. CONCLUSIONS AND RELEVANCE: A SMART approach to SCA prophylaxis prevents fatalities and is cost-effective in patients at elevated SCA risk. The availability of a smart-phone enabled pocket-sized AED with CPR prompts has the potential to greatly improve population health and economic outcomes. Frontiers Media S.A. 2022-02-24 /pmc/articles/PMC8907482/ /pubmed/35282380 http://dx.doi.org/10.3389/fcvm.2022.771679 Text en Copyright © 2022 Shaker, Abrams, Oppenheimer, Singer, Shaker, Fleck, Greenhawt and Grove. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Shaker, Marcus S.
Abrams, Elissa M.
Oppenheimer, John
Singer, Alexander G.
Shaker, Matthew
Fleck, Daniel
Greenhawt, Matthew
Grove, Evan
Estimation of Health and Economic Benefits of a Small Automatic External Defibrillator for Rapid Treatment of Sudden Cardiac Arrest (SMART): A Cost-Effectiveness Analysis
title Estimation of Health and Economic Benefits of a Small Automatic External Defibrillator for Rapid Treatment of Sudden Cardiac Arrest (SMART): A Cost-Effectiveness Analysis
title_full Estimation of Health and Economic Benefits of a Small Automatic External Defibrillator for Rapid Treatment of Sudden Cardiac Arrest (SMART): A Cost-Effectiveness Analysis
title_fullStr Estimation of Health and Economic Benefits of a Small Automatic External Defibrillator for Rapid Treatment of Sudden Cardiac Arrest (SMART): A Cost-Effectiveness Analysis
title_full_unstemmed Estimation of Health and Economic Benefits of a Small Automatic External Defibrillator for Rapid Treatment of Sudden Cardiac Arrest (SMART): A Cost-Effectiveness Analysis
title_short Estimation of Health and Economic Benefits of a Small Automatic External Defibrillator for Rapid Treatment of Sudden Cardiac Arrest (SMART): A Cost-Effectiveness Analysis
title_sort estimation of health and economic benefits of a small automatic external defibrillator for rapid treatment of sudden cardiac arrest (smart): a cost-effectiveness analysis
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907482/
https://www.ncbi.nlm.nih.gov/pubmed/35282380
http://dx.doi.org/10.3389/fcvm.2022.771679
work_keys_str_mv AT shakermarcuss estimationofhealthandeconomicbenefitsofasmallautomaticexternaldefibrillatorforrapidtreatmentofsuddencardiacarrestsmartacosteffectivenessanalysis
AT abramselissam estimationofhealthandeconomicbenefitsofasmallautomaticexternaldefibrillatorforrapidtreatmentofsuddencardiacarrestsmartacosteffectivenessanalysis
AT oppenheimerjohn estimationofhealthandeconomicbenefitsofasmallautomaticexternaldefibrillatorforrapidtreatmentofsuddencardiacarrestsmartacosteffectivenessanalysis
AT singeralexanderg estimationofhealthandeconomicbenefitsofasmallautomaticexternaldefibrillatorforrapidtreatmentofsuddencardiacarrestsmartacosteffectivenessanalysis
AT shakermatthew estimationofhealthandeconomicbenefitsofasmallautomaticexternaldefibrillatorforrapidtreatmentofsuddencardiacarrestsmartacosteffectivenessanalysis
AT fleckdaniel estimationofhealthandeconomicbenefitsofasmallautomaticexternaldefibrillatorforrapidtreatmentofsuddencardiacarrestsmartacosteffectivenessanalysis
AT greenhawtmatthew estimationofhealthandeconomicbenefitsofasmallautomaticexternaldefibrillatorforrapidtreatmentofsuddencardiacarrestsmartacosteffectivenessanalysis
AT groveevan estimationofhealthandeconomicbenefitsofasmallautomaticexternaldefibrillatorforrapidtreatmentofsuddencardiacarrestsmartacosteffectivenessanalysis